Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Tan

Showing results (611-620 of 640) with videos related to

Pageof 64
Sort By:
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
JCO Precision Oncology|July 12, 2021
ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and UrineBruna Pellini, Nadja Pejovic, Wenjia Feng, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 StudyErika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Pageof 64

Showing results (611-620 of 640) with videos related to

Sort By:
Pageof 64
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
JCO Precision Oncology|July 12, 2021
ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and UrineBruna Pellini, Nadja Pejovic, Wenjia Feng, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 StudyErika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Pageof 64